Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illness study for France, Germany, Italy, Spain and the UK

Abstract

The direct initial healthcare cost burden of the most common non-skin-related male cancer, prostate cancer, in France, Germany, Italy, Spain and the UK is considerable. Given the high and increasing prevalence of prostate cancer due to ageing populations in Europe, and the significant cost burden of the disease, national health policy makers should be aware of prostate cancer as a priority disease area.